Alfresa Holdings Corporation

While social security expenditures continue to rise due to population aging, cost-containment measures—such as the introduction of bundled payment systems for medical fees, promotion of generic drug adoption, and revisions to the drug pricing standard system—are being continuously implemented against a backdrop of deteriorating payment capacity of medical insurance funding sources. Significant changes to the system could have a material impact on the Group's operating results and other performance indicators. The Group is focusing on compliance with the Distribution Improvement Guidelines that came into effect in April 2018, while also promoting the expansion of products and services that are not affected by the healthcare system.

The prices of prescription pharmaceuticals, the Group's main products, are official prices (drug prices) set by public notice of the Minister of Health, Labour and Welfare, and function as a de facto ceiling on selling prices. Periodic downward revisions are made in accordance with actual market prices and demand trends, and each revision may affect the Group's operating results and other performance indicators.

The Group is required to comply with the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, the Antimonopoly Act, the Subcontract Act, the Financial Instruments and Exchange Act, and other laws and regulations. Violations could result in restrictions on business activities, increased response costs, and damage to social credibility. The Group has established Compliance Guidelines and works to ensure thorough legal compliance through the Group Compliance and Risk Management Committee and training programs.

The prescription pharmaceutical wholesale industry has a unique practice whereby, for a certain period after drug price revisions, products are delivered to medical institutions before prices are finalized, with price negotiations conducted afterward; sales are recorded at a reasonably estimated expected settlement price when negotiations are protracted. Prolonged negotiations or settlement at prices different from initial expectations may affect the Group's operating results and other performance indicators. The Group continues to work on distribution reform aimed at compliance with the Distribution Improvement Guidelines and early settlement of prices.

In the pharmaceutical manufacturing business, not all products under development are guaranteed to reach market launch, carrying the risk of discontinuation partway through, and there is also a risk of delay or suspension in procurement, manufacturing, and sales due to dependence on specific business partners for raw materials and product supply. There are additional risks of product recalls, discontinuation of sales, and litigation arising from unexpected side effects or foreign matter contamination. The Group has introduced a common quality control system at two domestic consolidated subsidiaries and is working to improve safety and reliability.

Dispensing operations are heavily dependent on pharmacists, and dispensing errors, if they occur, could lead to liability for damages and loss of social credibility. In addition, pharmacist staffing regulations under the Pharmacists Act, the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, and other laws may make it difficult to secure necessary personnel, potentially hindering the maintenance of existing pharmacies or the opening of new ones. The Group is working to prevent errors through appropriate staffing allocation, reassignment of additional personnel, and the introduction and utilization of dispensing audit systems.

Business activities are heavily dependent on computer network systems, and a system outage caused by a disaster or accident could disrupt sales and logistics-centered business operations. Recent sophistication and increasing complexity of cyberattack methods have also heightened risks of unauthorized access, virus infection, and information leakage. The Group addresses these risks by establishing data centers at multiple locations, conducting system monitoring through consolidated subsidiaries, and continuously strengthening cybersecurity measures.

The Group holds confidential information, customer information, personal information, and other sensitive data. An information leakage caused by an unforeseen event could result in loss of social credibility, liability for damages, suspension of business transactions, and compensation to affected parties, potentially affecting the Group's operating results and other performance indicators. The Group has established and thoroughly implements internal regulations based on relevant laws and regulations, and builds an information security framework based on unified Group standards, including education and operational checks.

Logistics functions play a major role in the pharmaceutical wholesale business, and damage to logistics functions caused by natural disasters such as earthquakes could disrupt sales and logistics activities. The Group has formulated a Business Continuity Plan (BCP) and disaster response manuals, established a list of stockpiled pharmaceuticals and a backup system using nearby facilities, and has established measures to prevent the spread of COVID-19 infections in coordination across the Group.

Large-scale, long-term infrastructure investments in logistics centers and sales offices, as well as investments in healthcare-related venture companies and M&A investments, all carry impairment risk, and the success or failure of such investments could have a material impact on the Group's operating results and other performance indicators. The Group has established a framework whereby investment projects above a certain scale are reviewed by the Business Investment Committee before being reported to the decision-making body, thereby working to reduce impairment risk.